IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,208 shares of the company’s stock after purchasing an additional 1,394 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in IDEXX Laboratories were worth $12,230,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of IDXX. Clearbridge Investments LLC increased its holdings in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after purchasing an additional 308,493 shares during the period. Vontobel Holding Ltd. grew its holdings in IDEXX Laboratories by 3,325.0% during the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after acquiring an additional 213,731 shares during the period. American Century Companies Inc. grew its holdings in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after acquiring an additional 177,226 shares during the period. 1832 Asset Management L.P. grew its holdings in IDEXX Laboratories by 4,193.1% during the second quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company’s stock worth $62,601,000 after acquiring an additional 125,498 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new position in IDEXX Laboratories during the first quarter worth about $55,425,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. Piper Sandler lowered their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. BTIG Research started coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Trading Down 0.5 %

Shares of NASDAQ IDXX opened at $457.74 on Friday. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The firm has a market capitalization of $37.80 billion, a PE ratio of 44.31, a PEG ratio of 4.14 and a beta of 1.33. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average price of $487.50 and a two-hundred day moving average price of $491.76.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business posted $2.67 earnings per share. The company’s revenue was up 6.4% compared to the same quarter last year. As a group, analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.